Merck (MRK) Could Be 7% Undervalued As MASH Trial Data Lifts Optimism
Merck (MRK) Could Be 7% Undervalued As MASH Trial Data Lifts Optimism Yahoo Finance
Covered in this story
Analyst targets on Merck & Co.
- Freedom Broker: at $149 · target $140 by Nov 2027 via Investing.com Canada
- Guggenheim: at $150 · target $171 by Oct 2027 · Buy via Investing.com
- RBC Capital Markets: at $145 · target $145 by Oct 2027 · Sector Perform via MarketBeat
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $MRK yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Merck & Co. →Dalsna Finance is currently tracking 37 stories mentioning Merck & Co., the earliest published 7 Apr 2026.
Summary aggregated from Yahoo Finance's public RSS feed. The full reporting belongs to Yahoo Finance — please read it on their site.